Is Supriya Lifesci. overvalued or undervalued?

As of 16 June 2025, the valuation grade for Supriya Lifesci. has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 29.63, an EV to EBITDA of 21.05, and a PEG ratio of 0.51, which indicates a relatively low growth expectation compared to its price.
In comparison to its peers, Sun Pharma has a higher PE ratio of 35.37 and an EV to EBITDA of 25, while Cipla is more attractively valued with a PE of 23.39 and an EV to EBITDA of 16.23. Despite recent stock performance showing a 73.59% return over the past year compared to the Sensex's 6.24%, the current valuation metrics suggest that Supriya Lifesci. is priced too high relative to its earnings potential and growth prospects.